Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use.

Capricor Therapeutics (NASDAQ:CAPR) lost ~15% on Friday after the cell therapy developer posted long-term data from an ...

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered ...

The ouster of the FDA's chief regulator of cell and gene therapies came immediately after a disagreement with her boss over a ...

Travis Kelce and Patrick Mahomes hosted Make-A-Wish kids at Kansas City Chiefs practice, offering gifts and unforgettable ...

After four years of continuous treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline. Further, a subgroup analysis of patients with baseline LVEF >45% ...

Fintel reports that on June 20, 2025, William Blair downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Max Fried says one Yankees slugger scared him more than any other originally appeared on Athlon Sports. Max Fried has faced ...

NEW YORK – Carmine and Vincent Gagliano, two brothers from Brooklyn, were living the dream on Thursday at Yankee Stadium. It was like watching two kids in the candy store. They love the Yankees that ...

Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...